Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile

Journal of Sexual Medicine

Volumn 9, Issue 1, 2012, Pages 169-179

  Araujo, Andre B ^a   Allen, Kerstin R ^a   Ni, Xiao ^b   Rosen, Raymond C ^a  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b Lilly Corporate Center   (United States)

Author keywords

Erectile Dysfunction; Event Log Measures; Men; Minimal Clinically Important Difference

Indexed keywords

TADALAFIL;

AGE; ANALYSIS OF VARIANCE; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; ERECTILE DYSFUNCTION; HUMAN; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; OUTCOME ASSESSMENT; PENIS ERECTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; STATISTICAL PARAMETERS; THERAPY; TREATMENT OUTCOME;

EID: 84855414324     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02506.x     Document Type: Article

References (17)

1. Cappelleri JC, Stecher VJ. An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer's perspective. Int J Impot Res 2008;20:343-57.
2. Schulman CC, Shen W, Stothard DR, Schmitt H. Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology 2004;64:783-8.
3. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. 2009.
4. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA; Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
5. Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, eds. Sexual medicine: Sexual dysfunctions in men and women. London: Health Publications Ltd; 2004.
6. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
7. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-6.
8. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004;93:1276-81.
9. Lewis RW, Sadovsky R, Eardley I, O'Leary M, Seftel A, Wang WC, Shen W, Walker DJ, Wong DG, Ahuja S. The efficacy of tadalafil in clinical populations. J Sex Med 2005;2:517-31.
10. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
11. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270:83-90.
12. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.
13. de Vet HC, Terwee CB, Ostelo RW, Beckerman H, Knol DL, Bouter LM. Minimal changes in health status questionnaires: Distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes 2006;4:54.
14. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: The minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62.
15. Cook CE. Clinimetrics corner: The minimal clinically important change score (MCID): A necessary pretense. J Man Manip Ther 2008;16:E82-3.
16. Kovacs FM, Abraira V, Royuela A, Corcoll J, Alegre L, Tomas M, Mir MA, Cano A, Muriel A, Zamora J, Del Real MT, Gestoso M, Mufraggi N. Minimum detectable and minimal clinically important changes for pain in patients with nonspecific neck pain. BMC Musculoskelet Disord 2008;9:43.
17. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9.